Results 121 to 130 of about 13,190 (254)

Why Do Cells Contain Thousands of Lipid Species? Toward an Integrated Framework for Lipid Diversity in Biological Membranes. [PDF]

Int J Mol Sci
Kim KH, Yoo BC.
europepmc   +1 more source

Integrating novel therapeutic strategies in myeloproliferative neoplasms: Driving disease‐directed progress

British Journal of Haematology, EarlyView.
Summary Over the past decade, there has been a substantial increase in the diversity and number of therapeutic options for myeloproliferative neoplasms (MPNs). While many remain within the clinical trial arena, the clinician and patient community have seen more approvals reaching the clinic and a rethink on how best we should be approaching these ...
Trung Q. Ngo, Maria Georgiou, Donal P. McLornan, Claire N. Harrison   +3 more
wiley   +1 more source

Editorial: Cell polarity: Trafficking and regulatory events that determine cell asymmetry

Frontiers in Cell and Developmental Biology, 2023
Andrés E. Zucchetti, James R. Goldenring, M. Cecilia Larocca   +2 more
doaj   +1 more source

A computational framework for the investigation of phosphoinositide regulation. [PDF]

PLoS Comput Biol
Cheung HYF, Tantiwong C, Kale D, Gibbins JM, Watson SP, Heemskerk JWM, Sickmann A, Ahrends R, Dunster JL.   +8 more
europepmc   +1 more source

Reduced colony‐stimulating factor 1 receptor expression in myeloid cells has limited impact on chronic lymphocytic leukaemia progression

British Journal of Haematology, EarlyView.
Summary Targeting the colony‐stimulating factor 1 receptor (CSF1R) to remove tumour‐associated macrophages is being explored as cancer therapy. This strategy may be relevant for chronic lymphocytic leukaemia (CLL), which strongly depends on support from myeloid cells.
Natascha Rosen, Guillermo Rodriguez‐Real, Alexander F. vom Stein, Luca D. Schreurs, Trong‐Hieu Nguyen, Viktoria Kohlhas, Thanh‐Tung Truong, Maximilian Koch, Sebastian Reinartz, Sumiya Iqbal, Shaista Ilyas, Sanjay Mathur, Nina Reinart, Phuong‐Hien Nguyen, Michael Hallek   +14 more
wiley   +1 more source

Potential endogenous lipid ligands for the nuclear receptor transcription factor Steroidogenic Factor-1. [PDF]

Adv Biol Regul
Campbell AN, Blind RD.
europepmc   +1 more source

The potential for biased signalling in the P2Y receptor family of GPCRs

British Journal of Pharmacology, EarlyView.
The purinergic receptor family is primarily activated by nucleotides, and contains members of both the G protein coupled‐receptor (GPCR) superfamily (P1 and P2Y) and ligand‐gated ion channels (P2X). The P2Y receptors are widely expressed in the human body, and given the ubiquitous nature of nucleotides, purinergic signalling is involved with a plethora
Claudia M. Sisk, Simon Pitchford, Graham Ladds   +2 more
wiley   +1 more source

Covalent drug discovery: Progress against key targets, emerging strategies and lessons learnt

British Journal of Pharmacology, EarlyView.
Abstract Covalent drug discovery is currently experiencing a boom in industrial and academic interest. To date, at least 75 covalent drugs have received regulatory approval, targeting both traditional target classes and more challenging proteins for which other approaches failed. In many cases, unique aspects of covalent targeting are essential for the
Charles P. Brown, Alan Armstrong, David J. Mann   +2 more
wiley   +1 more source

Long-tailed class I myosins rely on tail-mediated phosphoinositide recognition for specific membrane recruitment. [PDF]

Cell Commun Signal
Rajendraprasad G, Kyriazi D, Franz P, Bader A, Erent M, Uta P, Preller M, Scholz T, Tsiavaliaris G.   +8 more
europepmc   +1 more source

Cardiotoxicity of BRAF/MEK inhibitors

British Journal of Pharmacology, EarlyView.
Abstract Rapidly accelerated fibrosarcoma type B/B‐Raf proto‐oncogene, serine/threonine kinase (BRAF) and mitogen‐activated protein kinase (MEK) inhibitors have transformed outcomes in cancer therapy, particularly in melanoma. However, cardiovascular toxicities are increasingly recognized in real‐world clinical practice.
Katharina Seuthe, Valerie Lohner, Kevin Terre, Thomas Riffelmacher, Roman Pfister   +4 more
wiley   +1 more source